These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 36643861)
1. Formulation for the Targeted Delivery of a Vaccine Strain of Oncolytic Measles Virus (OMV) in Hyaluronic Acid Coated Thiolated Chitosan as a Green Nanoformulation for the Treatment of Prostate Cancer: A Viro-Immunotherapeutic Approach. Naseer F; Ahmad T; Kousar K; Kakar S; Gul R; Anjum S; Shareef U Int J Nanomedicine; 2023; 18():185-205. PubMed ID: 36643861 [TBL] [Abstract][Full Text] [Related]
2. CD44 targeted delivery of oncolytic Newcastle disease virus encapsulated in thiolated chitosan for sustained release in cervical cancer: a targeted immunotherapy approach. Kousar K; Naseer F; Abduh MS; Anjum S; Ahmad T Front Immunol; 2023; 14():1175535. PubMed ID: 37283735 [TBL] [Abstract][Full Text] [Related]
3. Co-delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro-chemotherapeutic approach. Anjum S; Naseer F; Ahmad T; Liaquat A; Abduh MS; Kousar K J Med Virol; 2024 Jul; 96(7):e29748. PubMed ID: 38975633 [TBL] [Abstract][Full Text] [Related]
4. Formulation for the Targeted Delivery of a Vaccine Strain of Oncolytic Measles Virus (OMV) in Hyaluronic Acid Coated Thiolated Chitosan as a Green Nanoformulation for the Treatment of Prostate Cancer: A Viro-Immunotherapeutic Approach [Retraction]. Int J Nanomedicine; 2024; 19():5719-5720. PubMed ID: 38895151 [TBL] [Abstract][Full Text] [Related]
5. Green synthesis of hyaluronic acid coated, thiolated chitosan nanoparticles for CD44 targeted delivery and sustained release of Cisplatin in cervical carcinoma. Kousar K; Naseer F; Abduh MS; Kakar S; Gul R; Anjum S; Ahmad T Front Pharmacol; 2022; 13():1073004. PubMed ID: 36712656 [TBL] [Abstract][Full Text] [Related]
6. Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer. Abduh MS Int J Nanomedicine; 2023; 18():5713-5732. PubMed ID: 37849642 [TBL] [Abstract][Full Text] [Related]
7. Enhancing therapeutic efficacy: sustained delivery of 5-fluorouracil (5-FU) via thiolated chitosan nanoparticles targeting CD44 in triple-negative breast cancer. Anjum S; Naseer F; Ahmad T; Jahan F; Qadir H; Gul R; Kousar K; Sarwar A; Shabbir A Sci Rep; 2024 May; 14(1):11431. PubMed ID: 38763930 [TBL] [Abstract][Full Text] [Related]
8. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133 [TBL] [Abstract][Full Text] [Related]
9. Opportunities to debottleneck the downstream processing of the oncolytic measles virus. Loewe D; Dieken H; Grein TA; Weidner T; Salzig D; Czermak P Crit Rev Biotechnol; 2020 Mar; 40(2):247-264. PubMed ID: 31918573 [TBL] [Abstract][Full Text] [Related]
10. [Synergistic Effect of NF-κB Signaling Pathway Inhibitor and Oncolytic Measles Virus Vaccine Strain against Lung Cancer and Underlying Mechanisms]. Xia M; Meng G; Dong J Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):245-253. PubMed ID: 33775041 [TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568 [TBL] [Abstract][Full Text] [Related]
12. The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus. Ammour Y; Ryabaya O; Shchetinina Y; Prokofeva E; Gavrilova M; Khochenkov D; Vorobyev D; Faizuloev E; Shohin I; Zverev VV; Svitich O; Nasedkina T Viruses; 2020 Feb; 12(2):. PubMed ID: 32033013 [TBL] [Abstract][Full Text] [Related]
13. Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy. Deng S; Iscaro A; Zambito G; Mijiti Y; Minicucci M; Essand M; Lowik C; Muthana M; Censi R; Mezzanotte L; Di Martino P Nanomaterials (Basel); 2021 Jan; 11(1):. PubMed ID: 33435600 [TBL] [Abstract][Full Text] [Related]
14. Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading. Xu C; Xia M; Meng G; Li C; Jiang A; Wei J Virol Sin; 2018 Jun; 33(3):234-240. PubMed ID: 29767404 [TBL] [Abstract][Full Text] [Related]
15. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma. Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685 [TBL] [Abstract][Full Text] [Related]
16. Hyaluronic Acid-Decorated Chitosan Nanoparticles for CD44-Targeted Delivery of Everolimus. Chiesa E; Dorati R; Conti B; Modena T; Cova E; Meloni F; Genta I Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30087241 [TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid-coated chitosan nanoparticles as targeted-carrier of tamoxifen against MCF7 and TMX-resistant MCF7 cells. Nokhodi F; Nekoei M; Goodarzi MT J Mater Sci Mater Med; 2022 Feb; 33(2):24. PubMed ID: 35157166 [TBL] [Abstract][Full Text] [Related]
18. Corrigendum: CD44 targeted delivery of oncolytic Newcastle disease virus encapsulated in thiolated chitosan for sustained release in cervical cancer: a targeted immunotherapy approach. Kousar K; Naseer F; Abduh MS; Anjum S; Ahmad T Front Immunol; 2024; 15():1391710. PubMed ID: 38529281 [TBL] [Abstract][Full Text] [Related]
19. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Msaouel P; Iankov ID; Allen C; Aderca I; Federspiel MJ; Tindall DJ; Morris JC; Koutsilieris M; Russell SJ; Galanis E Mol Ther; 2009 Dec; 17(12):2041-8. PubMed ID: 19773744 [TBL] [Abstract][Full Text] [Related]
20. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains. Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]